RxDoctor Payments Data

Wen-Chou Tang, MD

Family Medicine · Fort Wayne, INNPI 1033405626

Payments from drug & device makers

$6,192in general payments, 2019–2025

Across 349 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$757
  • AstraZeneca$621
  • AbbVie$581
  • Bayer$565
  • Lilly USA, LLC$527
  • Otsuka America Pharmaceutical, Inc.$426
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$6,10099%
  • Education$921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,192 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$2,937
Medicare patients
27
Services billed
77

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin63$97,098
VraylarCariprazine Hcl61$94,442
OzempicSemaglutide63$81,428
TrulicityDulaglutide47$75,224
EliquisApixaban78$64,606
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$52,950
MounjaroTirzepatide47$51,919
FarxigaDapagliflozin Propanediol33$40,631
LinzessLinaclotide34$31,513
JanuviaSitagliptin Phosphate20$26,807
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$19,477
QuliptaAtogepant14$17,805
Repatha SureclickEvolocumab13$11,795
Tresiba Flextouch U-100Insulin Degludec16$11,751
Soliqua 100-33Insulin Glargine/Lixisenatide14$9,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Linzess, Qulipta$581$143,759109 claims
Lilly USA, LLCTrulicity, Mounjaro$527$127,14294 claims
Boehringer IngelheimJardiance$17$97,09863 claims
Novo NordiskOzempic$757$81,42863 claims
PfizerEliquis$268$64,60678 claims
GSKTrelegy Ellipta$31$52,95054 claims
AstraZenecaFarxiga, Symbicort$621$46,14655 claims
MerckJanuvia$236$26,80720 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$82$9,87914 claims
Astellas Pharma US IncMyrbetriq$56$8,00112 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$1,761144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →